Seeking Alpha
 

Qiagen N.V. (QGEN)

- NASDAQ
  • Apr. 11, 2014, 5:37 PM
    | Comment!
  • Apr. 30, 2013, 9:10 AM
    Premarket gainers: HPY +10%. HTWR +9%. ANAD +9%. AVP +8%. UBS +7%. BBY +6%.
    Losers: DCTH -20%. AVEO -16%. NUAN -15%. PBI -10%. MTG -8%. CNH -6%. RVBD -6%. QGEN -5%.
    | Comment!
  • Nov. 5, 2012, 11:24 AM
    Qiagen (QGEN +1.1%) gains after its Q3 beat on all counts this morning. On paper, net earnings fell 17% Y/Y, but that number is skewed from a one-time acquisition gain, which masked a 10% rise in total revenue over the same period last year. The company has struggled in recent quarters as patients reduced their use of health-care services, but early this year the company completed a streamlining process which gave a big boost to bottom line margins.
    | Comment!
  • Jul. 2, 2012, 3:23 PM
    Qiagen (QGEN +1.7%) trades up after Goldman upgraded the shares to Neutral today, based on reduced risk to 2012 estimates and an M&A premium due to the scarcity value of its assets.
    | Comment!
  • Jun. 28, 2012, 11:41 AM
    Piper Jaffray says the Supreme Court's decision is positive for companies exposed to doctors' offices, with Genomic Health (GHDX -0.8%) likely the biggest beneficiary. Other names that should benefit include: Gen-Probe (GPRO +0.1%), Hologic (HOLX -1.6%), Qiagen (QGEN -1.8%), EXACT Sciences (EXAS -2.8%) and Meriad Genetics (MYGN +0.2%).
    | Comment!
  • Jan. 25, 2012, 10:02 AM
    The hostile bid from Roche to take over Illumina spills over to more names (previous: PACB, GNOM, LIFE) on M&A speculation - as Sequenom (SQNM +2.2%), Qiagen (QGEN +1.5%), and Luminex (LMNX +1.1%) all catch bids in early trading.
    | Comment!
  • Jan. 4, 2012, 7:53 AM
    Qiagen (QGEN) rallies after JPMorgan raises its rating on the Dutch biotech firm to Overweight from Neutral. Shares +4.1% in Frankfurt trading, +3.5% premarket.
    | Comment!
  • Nov. 3, 2011, 9:00 AM
    Premarket gainers: MDVN +124%. FIO +16%. NBG +15%. ARO +13%. ING +13%. ANR +12%. PSTI +12%. QCOM +10%. QGEN +8%. ALU +7%. TS +7%. BCS +7%. YRCW +7%. AEO +7%. DB +5%. STX +5%. PCX +5%. LYG +5%. SWKS +5%. GPS +4%. E +4%. MS +4%. LNG +4%. PHG +3%. NOK +3%. TRH +3%. FTE +3%. RTK +3%. ONNN +3%. AU +3%. BAC +3%. MPEL +3%. HL +3%. C +3%. FCX +3%. TOT +3%. SNY +3%. AKS +3%.
    Losers: DNDN -27%. ANF -19%. GMXR -13%. WFR -10%. RIG -8%. WTSLA -7%. K -7%. NTRI -5%. CLWR -5%. TGP -5%. LTD -4%. M -3%.
    | Comment!
  • Nov. 2, 2011, 4:08 PM
    Qiagen (QGEN): Q3 EPS of $0.24 beats by $0.02. Revenue of $289M (+5% Y/Y) misses by $1M. (PR)
    | Comment!
  • Oct. 12, 2011, 9:05 AM
    Premarket gainers: LIZ +42%. AONE +15%. FRO +10%. ONXX +8%. TEL +7%. ALU +7%. BCS +6%. ING +5%. ASML +5%. DB +5%. MT +5%. RBS +5%. MPEL +5%. GNW +5%. CS +4%. DRYS +4%. YRCW +3%. SIRI +3%. S +3%. BHP +3%. NOK +3%. FCX +3%. UBS +3%. QGEN +3%. AU +3%. MCP +3%. RIO +3%.
    Losers: CHKM -5%. PCX -5%. PWER -4%. AT -4%. AA -4%. HST -3%. FSLR -3%.
    | Comment!
  • Oct. 5, 2011, 9:00 AM
    Premarket gainers: EK +10%. ALU +7%. AMR +5%. TPST +5%. DRYS +4%. NBG +3%.
    Losers: APKT -15%. SPIL +5%. STD -4%. QGEN -3%. MS -3%.
    | Comment!
  • Sep. 29, 2011, 12:24 PM
    Shares of Qiagen NV (QGEN +3%) are up today after Leerink Swann raises it to outperform on valuation, winning out over a same-day competitor downgrade of the shares to neutral by Mizuho.
    | Comment!
  • Aug. 5, 2011, 8:52 AM
    Qiagen (QGEN) announces it has submitted an approval application to the FDA for its Erbitux treatment for colorectal cancer. The firm says its pipeline of healthcare assays includes a submission in 2012 for an EGFR biomarker test for use with an anticancer medicine for patients with a form of lung cancer. Shares +6.3% premarket. (PR)
    | Comment!
  • Jul. 26, 2011, 9:00 AM
    Premarket gainers: SONE +29%. APP +23%. RSH +19%. GRA +9%. SVU +8%. BRCM +9%. CIGX +8%. WFT +8%. BIDU +6%. CMI +6%. COV +5%. RENN +4%. YOKU +3%. GSK +3%.
    Losers: LII -11%. VDSI -9%. EK -9%. STM -9%. NFLX -8%. FNDT -7%. WAT -7%. AKS -6%. QGEN -3%. NVDA -3%. MMM -3%.
    | 1 Comment
  • Jul. 25, 2011, 5:17 PM
    Qiagen (QGEN): Q2 EPS of $0.23 in-line. Revenue of $282M (+7% Y/Y). Shares -3.3% AH. (PR)
    | Comment!
  • Jul. 25, 2011, 8:37 AM
    Wedbush downgrades Qiagen (QGEN) to neutral, citing the worsening EU situation and increased risks from Cepheid (CPHD) HPV competition. Shares -1.68% premarket.
    | Comment!
Visit Seeking Alpha's
QGEN vs. ETF Alternatives
Company Description
Qiagen NV provides sample and assay technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics.
Sector: Healthcare
Industry: Biotechnology
Country: United States